Home   Join  
News & city
London news
Olympic bid

London jobs
Homes & property
Travel Ads

Site & web search
London Music Network
Who do you trust with your money?
Cheaper phone bills
Cheaper gas/electricity
Picture galleries
Bigley crisis
Christopher Reeve
The Beckhams' bad year
All picture galleries
Advertise with us
Contact/update us

Story tools:
Back a page
Read later
Mail to a friend

New attack on Glaxo's Seroxat
4 October 2004

DRUGS giant GlaxoSmithKline has vigorously denied once again that it tried to hide results or mislead regulators or the medical community over paediatric clinical trial data for its antidepressant Seroxat.

Glaxo repeated that it is co-operating fully with the Medicines and Healthcare products Regulatory Authority's ongoing investigation which started this year.

The BBC's Panorama programme last night claimed that vital information on the side effects of the drug have been lying dormant in the MHRA files for at least 13 years.

The Panorama programme claimed that past trial results on the drug contain evidence it may increase the risk of suicide in young adults.

The programme also said that the trials had evidence that the drug can leave a quarter of users addicted, while rapid increases in its dosage can cause serious side effects.

Panorama alleged some of the evidence could have been spotted earlier by the MHRA.

The MHRA denies the allegations while GlaxoSmithKline said the drug's effectiveness had been demonstrated in clinical trials involving more than 24,000 people.

 Top of page
©2004 Associated New Media | Terms | Privacy policy

Today in London

Save money! Find a cheaper phone line

Mortgage advice: Save money here

This is Money: Personal finance advice
Comment & Analysis

Pat Lay's
small caps, This Is Money

Your inside track on one of the stock market's most exciting sectors

Lisa Buckingham, Mail on Sunday
The Financial Mail Editor says Rose is rewarding M&S faithful on the cheap

The Interview, Mail on Sunday
Ben Laurance meets the man on a mission to fix our pensions

Stockwatch, This Is Money
Our charting expert sees the foundations starting to look shaky at Bellway